GlassScriptPhysician profile
Crystal D Ball
NPI 1053863688
$2,510.85
in general payments reported to CMS, 2019-2025
18 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $297 · 2022: $1,000 · 2023: $550 · 2024: $414 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,214.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $960.67 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $453.05 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $306.86 | 2021-2023 | |
| Lilly USA, LLC | $189.63 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $150.29 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.39 | 2023-2025 | Xifaxan |
| Inogen, INC. | $75.76 | 2022-2024 | Inogen At Home Stationary Concentrator |
| Biohaven Pharmaceutical Holding Company LTD. | $52.76 | 2022 | |
| Exact Sciences Corporation | $40.05 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $38.09 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $35.14 | 2022-2023 | |
| Pfizer INC. | $28.94 | 2021-2024 | |
| Glaxosmithkline, LLC. | $23.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.56 | 2022 | |
| Insulet Corporation | $16.00 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $14.65 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.44 | 2021 | |
| Impel Pharmaceuticals INC. | $13.07 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.